PRELIMINARY STUDY OF A NOVEL HUMAN PAPILLOMAVIRUS TYPE 16L1／E6-E7 CHIMERIC RECOMBINANT DNA VACCINE

Objective Preparations of HPV16 L1/E6 and L1/E7 prophylactic and therapeutic DNA vaccines. Methods The nucleotides within HPV16 E6 and E7 genes, which are responsible for viral transforming activity, were mutated by mage primer site-directed mutagenesis method. The correctly mutated E6 and E7 fragments were separately cloned into an eukaryotic expression vector pVAX1, together with HPV16 L1 gene, generating chimeric recombinants plasmids 1MpVAX1-L1E6, 2MpVAX1-L1E6, 1MpVAX1-L1E7, 2MpVAX1-L1E7 and 3MpVAX1-L1E7. CHO cells were transiently transfected with the individual DNA vaccines by calcium phosphate method. Target protein expressions in the extracts of the transfected cell lines were measured by ELISA and immunohistochemistry, with HPV16 L1 and E6 specific monoclonal antibodies. Results ELISA assays showed the P/N ratios in the cell extracts transfected with L1E6 and L1E7 plasmids were more than 2.1. Immunohistochemistry revealed brownish precipitant signal in cytoplasm and nuclei of the transfected cells. Conclusion Successful constructions of prophylactic and therapeutic DNA vaccine plasmids lay solid foundation for future animal experiment and clinical trial.     

MAPPING EPITOPES OF HUMAN PAPILLOMAVIRUS TYPE 16 L1 PROTEIN WITH A PHAGE DISPLAY EPITOPE LIBRARY

Theinfectionofhumanpapillomavirus(HPV)isakindofcommonsexuallytransmitteddiseases.Thehigh-riskgroupHPV,especiallyHPV16iscolselyassociatedwithhumancervicalcancer,anditwasindicatedasaninitiationfactorofcervicalcancertl].HPV16FIgenelocatedinlateopenreadingframesoftheviralgenomeencodesthemajorcoatprotein,LIprotein,whichcouldassembleintoviruslikeparticles(VLP)aloneintheinfectiousnucleit23.AbatchofevidencesshowedthattheLIproteincouldinduceantibodieswithhightiterinthehostandtheantibodiesmightp…     

DIG－DNA探针检测宫颈癌组织中HPV－16的E_7转化基因

应用地高辛配基（Ｄｉｇ－１１－ｄＵＴＰ）标记人乳头瘤病毒１６型（ＨＰＶ－１６）Ｅ７转化基因作探针，分别检测了宫颈癌活检组织、宫颈炎及正常宫颈脱落细胞ＤＮＡ。其检出率为：宫颈癌中４２．１％（２４／５７）、宫颈炎中２．５％（１／３９）、正常宫颈中５．５％（１／１８）。宫颈组织中ＨＰＶ－１６Ｅ７转化基因的检出率较高，提示该转化基因与宫颈癌的发生可能密切相关。本研究也证实ＤＩＧ配基标记的Ｅ７基因探针具有特异、敏感、安全、稳定和能反复使用的优点，适合基层使用。     

人子宫颈癌中的HPV_(16)E_6mRNA、p~(53)、P~(21)~(ras)和c-myc蛋白表达

为进一步探讨子宫颈癌的分子发病机制，采用PCR、ISH和IHC方法对51例子宫颈癌组织的HPV16感染、HPV16E6mRNA、p53、p21ras和c－myc蛋白表达分布进行了研究。结果表明51例中有HPV16感染者38例，HPV16E6mRNA表达者35例，其阳性细胞主要分布在高分化癌巢之周边部或中、低分化癌之整个癌巢；p53、p21ras和c－myc蛋白阳性检出率分别为33．3％、60．8％和76．5％，其阳性细胞是弥漫或灶状分布。统计分析表明HPV16感染与P53、P21ras、c－myc蛋白积累间无关，但后三者间则显著相关。这提示癌基因活化或抗癌基因的失活及HPV16感染等因素之协同在子宫颈癌的发生发展中起重要作用。     

THE CONSTRUCTION OF HPV16 L1 RECOMBINANT PLASMID AND ITS EXPRESSION IN MAMMALIAN CELLS

Ｐｒｅｖｉｏｕｓｓｔｕｄｉｅｓｈａｖｅｄｅｍｏｎｓｔｒａｔｅｄｔｈａｔｇｅｎｉｔａｌｉｎｆｅｃｔｉｏｎｗｉｔｈｈｉｇｈ－ｒｉｓｋｔｙｐｅｓｏｆｈｕｍａｎｐａｐｉｌｌｏｍａｖｉｒｕｓ（ＨＰＶ）,ｍｏｓｔｏｆｔｅｎＨＰＶ１６,ａｒｅｔｈｅｍｏｓｔｓｉｇｎｉｆｉｃａｎｔｒｉｓｋｆａｃｔｏｒｆｏｒｔｈｅｄｅｖｅｌｏｐｍｅｎｔｏｆｃｅｒｖｉｃａｌｃａｎｃｅｒ．ＨＰＶ１６ｓｔｒｕｃｔｕｒａｌｐｒｏｔｅｉｎｓａｎｄｎａｔｉｖｅｖｉｒｉｏｎｓｏｎｌｙｅｘｉｓｔｉｎｄｉｆｆｅｒｅｎｔｉａｔｅｄｓｕｐｅｒｆｉｃｉａ…     

真核表达人乳头瘤病毒16型L_1蛋白在检测宫颈癌患者相应抗体的应用

用真核表达HPV16L1蛋白为抗原，酶联免疫吸附测定64例宫颈癌患者血清和阴道分泌物的相应抗体，并用型特异性聚合酶键反应检测宫颈癌组织HPV16L1基因。结果：宫颈癌组血清HPV16L1抗体阳性年64．1％，对照组20．8％；宫颈癌组阴道分泌物HPV16L1抗体阳性率64.1％，对照组25％；宫颈癌组HPV16L1基因检出率为42．2％，对照组10％。有显著差异（P＜0．01）。结论：高危型HPV感染，宫颈癌患者有明显免疫反应，全身和局部无明显差异，真核表达HPV16L1蛋白可用于宫颈癌患者的抗体测定。